Skip to content
City PM
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
Wednesday 23 June 2021 9:44 am

‘Science superpower’: UK to pump £64m into post-pandemic clinical research

By: Millie Turner

Add as a preferred source on Google
“It’s a little bit of a dangerous trend” - Soumya Swaminathan

The government has pledged a £64m injection into the UK’s clinical research system, off the back of Boris Johnson’s plans to make the country a “science superpower”.

The investment will go towards the development and trial of new Covid-19 treatments and inoculations, to ensure a “front-footed approach in tackling the virus”, health secretary Matt Hancock said. 

“Clinical research has been vital in our fight against Covid-19 and has saved thousands of lives,” Hancock added.

“The link between research and benefit to patients through better treatments and care has never been clearer.”

Funds will also go towards boosting capacity for more virtual and remote trials and smoother delivery through quicker ethics reviews and speedier approval processes.

As well as towards digitising current processes to allow researchers to find patients and offer them places in trials, alongside monitoring health outcomes.

After Black, Asian and ethnic minority communities were revealed to have been disproportionately impacted by the virus, the injection also seeks to increase diversity and participation in research in communities traditionally under-served.

The government aims to increase research spending from nearly £15bn a year to £22bn by 2025, it was reported on Monday.

Building on the success of the vaccine rollout, prime minister Johnson will also chair a new National Science and Technology Council to provide “strategic direction” on how research is used for the “public good”.

Read more

IMU Biosciences Selects Waters to Advance Breakthrough AI Immune Mapping Platform to Transform Early Diagnosis, Monitoring, and Precision Medicine

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business
  • Politics
  • Tech

Related Topics

  • Boris Johnson
  • Coronavirus
  • Covid-19 a year on
  • Matt Hancock

Trending Articles

  • Top Burnham adviser calls for capital gains and inheritance tax hikes

  • A meeting with the breakfast king of Mayfair

  • As it happened: Stocks jump on defence and metals boost; Oil on track to shed a fifth on US-Iran peace hopes

  • Clarkson’s Farm and why businesses must stop blaming the weather

  • Housebuilding giants hit with £4.5bn lawsuit for allegedly overcharging buyers

More from City PM

  • IMU Biosciences Selects Waters to Advance Breakthrough AI Immune Mapping Platform to Transform Early Diagnosis, Monitoring, and Precision Medicine

    Business Wire
  • Anocca has Dosed First Patients with Precision TCR-T Cell Therapy Targeting Mutant KRAS in Pancreatic Cancer

    Business Wire
  • Overture Life Launches Global ICSI.A Center of Excellence Program, Bringing the World’s First Automated ICSI into Clinical Use Across Five Leading Global Fertility Centers

    Business Wire
  • cTAP Announces Novel Prognostic Score Developed for Duchenne Muscular Dystrophy Patients Offers Improved Prediction of Loss of Ambulation

    Business Wire
  • IMU Biosciences announces oversubscribed financing round, bringing its Series A to over $53M as it accelerates its work to decode the immune system with unprecedented resolution and scale, to transform how we understand, diagnose and treat disease

    Business Wire
  • Reply and IEO Launch Collaboration to Co-Develop and Train Domain-Specific Large Language Models for Oncology

    Business Wire
  • ICON selects Microsoft as a preferred technology partner to power AI-enabled clinical development

    Business Wire
  • Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe

    Business Wire

City PM — European politics, business and analysis.

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Topics

  • Business
  • Markets
  • AI
  • Technology
  • Opinion
  • Energy

More

  • Politics
  • Economics
  • Fintech
  • Legal
  • Sport
  • Life

Company

  • About City PM
  • Editorial Policy
  • Corrections
  • Contact
  • Terms of Use
  • Privacy Policy
  • Cookie Policy
© 2026 City PM · Published by CityPM Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
About · Editorial Policy · Corrections · Contact · Privacy